14.59 stock price down
Change
- 0.16 (1.08%)
Volume
1,400
Exchange
NASDAQ
3:28 PM ET on Jul 25, 2014
Delayed at least 20 minutes.
Provided by eSignal.
5.01 stock price down
Change
- 0.07 (1.46%)
Volume
71,645
Exchange
TASE
2:24 PM IT on Jul 24, 2014
Delayed at least 20 minutes.
Provided by eSignal.
View all »Recent Releases

Jul 23, 2014
RedHill Biopharma Reports Results for the Second Quarter of 2014

Jul 16, 2014
RedHill Biopharma to Host Second Quarter 2014 Financial Results Conference Call on July 24, 2014

Jun 30, 2014
RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON(R) From WILEX AG

Investor Relations (US):

Lauren Glaser
Vice President
The Trout Group LLC
Direct: +1 646 378 2972
Cell: +1 215 740 8468
email: lglaser@troutgroup.com

Investor Relations (Israel):

Eran Gabay
Vice President & Managing Director
Financial PR and Strategic Communications
Gelbart-Kahana Investor Relations
Direct: +972 (0)3 6070 591
email: erang@gk-biz.com

General:

RedHill Biopharma Ltd.
21 Ha’arba’a St., Tel-Aviv 64739, Israel
Tel: +972 (0)3 541 3131
Fax: +972 (0)3 541 3144
email: info@redhillbio.com